Facebook Twitter LinkedIn Google Plus RSS

Salix Pharma teams to offer opioid-withdrawal drug

By ,

Bridgewater-based Salix Pharmaceuticals and Kentucky-based US WorldMeds LLC have brought to market the first and only FDA-approved nonopioid medication to temper symptoms of withdrawal caused by the stoppage of opioid-use.

The drug, Lucemyra, received approval from the U.S. Food and Drug Administration in May. In June, Salix and US WorldMeds entered into a co-promotional deal for the medication.

According to the companies, Lucemyra works by reducing the release of norepinephrine, a neurotransmitter, to suppress rushes from the nervous system that produce opioid withdrawal. The drug was developed through a collaboration with, and grant from, the National Institute on Drug Abuse, part of the National Institutes of Health.

“By effectively intervening during withdrawal and helping to control severe, disabling withdrawal symptoms, Lucemyra can help provide a starting point toward recovery,” Salix President Mark McKenna said in a release.

Lucemyra is an oral tablet. The most common side effects are low blood pressure, lightheadedness, slow heart rate, dizziness, sleepiness and dry mouth.

Qualifying patients can receive the prescription drug per a co-pay program associated with the launch offering prices for as low as $25.

More From This Industry

Jessica Perry

Jessica Perry

Jessica is the Web Editor for NJBIZ. You can reach her at jperry@njbiz.com.

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy